Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events
In the largest sleep apnea study ever conducted, continuous positive airway pressure (CPAP) did not appear to lower the risk of cardiovascular adverse events including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina in patients with obstructive sleep apnea and known cardiovascular disease. However, patients in the trial only used CPAP a few hours a night, on average, indicating that an easier-to-use version of CPAP might yield better outcomes.
You may also be interested in...
The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.
An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.